Related Experiment Video
Updated: Jul 2, 2025
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
Association of Alkaline Phosphatase with Cardiovascular Disease in Patients with Dyslipidemia: A 6-Year Retrospective
Petros Spyridonas Adamidis1, Matilda Florentin1, Evangelos Liberopoulos2
1Department of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece.
Serum alkaline phosphatase (ALP) is linked to atherosclerotic cardiovascular disease (ASCVD) in dyslipidemia patients. Higher ALP levels correlate with increased ASCVD risk, suggesting ALP
Area of Science:
- Cardiovascular Medicine
- Biochemistry
- Clinical Research
Background:
- Serum alkaline phosphatase (ALP) activity is recognized for its association with atherosclerotic cardiovascular disease (ASCVD).
- Patients with dyslipidemia represent a population at heightened risk for ASCVD.
- The specific role of ALP in ASCVD development within this patient group requires further elucidation.
Purpose of the Study:
- To investigate the association between baseline serum alkaline phosphatase (ALP) levels and the incidence of atherosclerotic cardiovascular disease (ASCVD).
- To determine if ALP can serve as a predictive marker for ASCVD in individuals diagnosed with dyslipidemia.
- To explore the potential of ALP as a therapeutic target for ASCVD prevention in dyslipidemic patients.
Main Methods:
- A retrospective cohort study was conducted involving adult patients with dyslipidemia.
- Participants were followed for a minimum of three years, with data collected between 1999 and 2022.
- Baseline ALP levels were stratified into tertiles (low, middle, high) and analyzed for association with incident ASCVD, adjusting for traditional cardiovascular risk factors and treatments.
Main Results:
- A cohort of 1178 patients with dyslipidemia was analyzed, with a median follow-up of 6 years.
- A statistically significant association was found between higher baseline ALP levels and an increased risk of incident ASCVD (OR: 6.99, p=0.001).
- Patients in the highest ALP tertile exhibited significantly higher odds of developing ASCVD compared to those in the lowest tertile (OR: 2.35, p=0.008).
Conclusions:
- The study demonstrates a significant association between serum alkaline phosphatase (ALP) levels and the development of atherosclerotic cardiovascular disease (ASCVD) in patients with dyslipidemia.
- These findings suggest that ALP may function as a valuable predictive biomarker for ASCVD in this specific patient population.
- The results highlight the potential utility of targeting ALP for therapeutic interventions aimed at preventing ASCVD.
More Related Videos
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
08:20Investigating the Protective Effects of Platycodin D on Non-Alcoholic Fatty Liver Disease in a Palmitic Acid-Induced In Vitro Model
Published on: December 2, 2022
Related Concept Videos
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...